Kristall einer Chinolinsubstituierten Verbindung

Details

Veröffentlichungs-Nr.

EP4722218

Anmeldetag

30. Mai 2024

Veröffentlichung

5. Dezember 2024

Rechtsraum

EP

Abstract

An object is to provide a crystal of a compound having an EGFR inhibition ability or a salt thereof, the crystal being satisfactory in one or more of the following characteristics: stability (in terms of heat or purity) and/or low hygroscopicity. According to one aspect of the present invention, there is provided a crystal form of (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]lindolizin-8-yl)acrylamide having a peak at a predetermined diffraction angle (2θ±0.2°) in its powder X-ray diffraction spectrum.

Anmelder

Firma

Taiho Pharmaceutical Co., Ltd.

Land

🇯🇵 Japan